Clorox (CLX) Stock Plunges to 52-Week Low Following Reduced Fiscal 2026 Outlook

Key Takeaways

• Clorox shares plummeted to a 52-week low of $88.38, representing a 27.25% decline year-over-year
• Third-quarter FY2026 earnings per share of $1.64 exceeded expectations by $0.10, though revenue outlook disappointed
• The company anticipates approximately 6% decline in net sales for the full fiscal year 2026
• Leading Wall Street firms including Goldman Sachs, UBS, Morgan Stanley, and Evercore ISI reduced their price targets
• Analysts express reserved sentiment despite the company’s quarterly earnings outperformance

Shares of Clorox (CLX) tumbled to a fresh 52-week low on May 1, initially touching $91.00 before declining further to $88.38. The consumer goods giant has shed 27.25% of its value over the trailing twelve months.

The Clorox Company, CLX

The sharp decline followed the company’s third-quarter fiscal 2026 earnings report released on April 30, which included a downward revision to its annual guidance.

At first glance, the quarterly results appeared solid. Adjusted earnings per share reached $1.64, surpassing Wall Street’s consensus estimate of $1.55 by a dime. Quarterly revenue totaled $1.67 billion, meeting analyst projections.

However, the company’s forward-looking statements painted a less optimistic picture. Management now anticipates net sales will contract by approximately 6% during fiscal year 2026—a significant deterioration from earlier expectations.

The adjusted earnings per share forecast for the complete fiscal year was similarly lowered to a range of $5.45 to $5.65, down considerably from the previous guidance of $5.95 to $6.30.

Shares declined roughly 2% in the immediate aftermath of the earnings announcement.

Major Investment Banks Reduce Price Forecasts

The diminished outlook prompted several prominent Wall Street institutions to lower their price objectives for Clorox.

Goldman Sachs slashed its price target to $83 from $94, explicitly attributing the reduction to the company’s weakened guidance.

UBS decreased its target from $110 to $96 while maintaining its Neutral stance on the stock. Morgan Stanley similarly reduced its forecast to $97 from $110, highlighting headwinds in specific product segments.

Evercore ISI lowered its target to $110 from $115, noting that third-quarter performance benefited from the termination of Glad’s royalty payment obligations—a non-recurring advantage that won’t persist.

Fundamental Metrics Present Contrasting Signals

Clorox currently trades at a price-to-earnings multiple of 15.76x, which certain market observers consider reasonable relative to its earnings power. According to InvestingPro analysis, the shares appear undervalued at present price levels.

The company’s GF Score stands at 68 out of 100. While profitability metrics earn a solid 7/10 rating, growth receives a concerning 1/10 score—particularly problematic within the highly competitive consumer products sector.

Financial strength garners a 4/10 assessment, suggesting potential vulnerabilities regarding leverage and liquidity management.

Management indicated that the GOJO acquisition should provide some revenue offset to the projected decline, though the overall outlook remains guarded.

Insider transaction activity has been relatively quiet over the past year—two purchase transactions and a single sale valued at approximately $1.86 million.

The company’s market capitalization currently stands at roughly $11.66 billion, representing a substantial decrease from valuations twelve months prior.

The new 52-week low of $88.38 marks the latest milestone in what has been a persistent downward trend throughout this fiscal period.

The post Clorox (CLX) Stock Plunges to 52-Week Low Following Reduced Fiscal 2026 Outlook appeared first on Blockonomi.